
Please try another search
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient’s overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Ellen M. Zane | 69 | 2018 | Independent Chairman |
Robert E. Abernathy | 67 | 2017 | Independent Director |
Mark W. Kroll | 69 | 2006 | Independent Director |
Charles J. Dockendorff | 67 | 2014 | Independent Director |
Michael J. Coyle | 61 | 2020 | Independent Director |
Claire Pomeroy | 68 | 2019 | Independent Director |
Martin Schreiber | - | - | Member of Scientific Advisory Council |
Jonathan Waters | - | - | Member of Scientific Advisory Council |
Marlene S. Williams | - | - | Member of Scientific Advisory Council |
Lloyd Emerson Johnson | 69 | 2021 | Independent Director |
Michael F. Murphy | - | - | Member of Scientific Advisory Council |
Melissa Cushing | - | - | Member of Scientific Advisory Council |
James Grotta | - | - | Member of Scientific Advisory Council |
Donat R. Spahn | - | - | Member of Scientific Advisory Council |
Kai Zacharowski | - | - | Member of Scientific Advisory Council |
Edward L. Snyder | 77 | - | Member of Scientific Advisory Council |
Bryan A. Cotton | - | - | Member of Scientific Advisory Council |
Paul N. Ness | - | - | Member of Scientific Advisory Council |
Marco Ranucci | - | - | Member of Scientific Advisory Council |
Steven Frank | - | - | Member of Scientific Advisory Council |
Diane M. Bryant | 62 | 2023 | Independent Director |
Christopher A. Simon | 60 | 2016 | CEO, President & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review